Johnson & Johnson (JNJ) announced new longer-term follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating RYBREVANT (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET. The study assessed RYBREVANT in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Results demonstrated that more than 70 percent of patients in the first-line subgroup responded to treatment with amivantamab plus chemotherapy, with most responses lasting beyond 16 months. These findings highlight the potential of RYBREVANT to deliver durable benefit in a difficult-to-treat patient population.
Notably, encouraging responses were also observed in patients with liver metastases, a group that typically faces poorer outcomes with colorectal cancer. The study further showed low rates of treatment-related discontinuations, underscoring the tolerability of the regimen.
The promising anti-tumor activity and durability of responses support continued investigation of RYBREVANT in ongoing Phase 3 studies for both first- and second-line colorectal cancer treatment.
Johnson & Johnson closed trading on January 9 at $204.39, down $1.36 or 0.66% during regular market hours. In after-hours trading, the stock edged higher to $204.98, gaining $0.59 or 0.29%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.